Ertapenem
Educational summary, not a formulary. Dosing is quoted from the Makindo chapters and topics site. The other sections are draft summaries not yet checked line by line against the BNF or SPC. Check dose, indication, interactions and monitoring in the BNF entry for Ertapenem and local guidelines before prescribing.
Mechanism
Carbapenem inhibiting cell-wall synthesis; once-daily dosing.
Uses
Intra-abdominal and pelvic infection, ESBL infections, diabetic foot and complicated urinary infection.
Dosing
No dose is given in the chapters. See the BNF.
Side effects
Diarrhoea, nausea, headache, injection-site reactions, seizures (rare).
Interactions
Valproate levels fall markedly (avoid); probenecid raises levels.
Contraindications and cautions
Beta-lactam anaphylaxis, valproate treatment
Monitoring
Renal function, seizures
Pregnancy and breastfeeding
Use if necessary
Renal and hepatic impairment
Halve dose if CrCl below 30
Overdose and reversal
Supportive
Special advice
No activity against Pseudomonas or Acinetobacter; adjust in renal impairment; seizure caution.
More from the textbook: uses, cautions and other points
- Meropenem / ertapenem | ESBL and severe sepsis; reserve; seizures; lowers valproate.
ID: How Infection Happens - Treatment - serious infections usually need a carbapenem (meropenem or ertapenem); alternatives by sensitivity (piperacillin–tazobactam sometimes, temocillin, aminoglycosides); oral options for UTI - nitrofurantoin, fosfomycin, pivmecillinam.
ID: Hospital infection, the immunocompromised host, vaccination and public health - Cell wall | Carbapenems | Meropenem, ertapenem (no Pseudomonas cover) | Very broad - reserve for ESBL and severe infection
Microbiology: Diagnostic microbiology, antimicrobials and resistance